Targets › BLMH
1 program from 1 company in 2 trials: 2 Phase 2; Oncology, Other; next expected readout Jun 2031.
The normal physiological role of BLM hydrolase is unknown, but it catalyzes the inactivation of the antitumor drug BLM (a glycopeptide) by hydrolyzing the carboxamide bond of its B-aminoalaninamide moiety thus protecting normal and malignant cells from BLM toxicity. (UniProt, Q13867)
Open in Phaseline: the race on BLMH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Institute of Oncology Ljubljana | Bleomycin Sulfate DNA-damaging chemotherapy agent; internalization enhanced by electroporation | BLMH | Phase 2 | Vulvar Cancer; Vascular Malformations | Jun 2031 |
Vulvar Cancer (1) Vascular Malformations (1)
small molecule (1)
Institute of Oncology Ljubljana (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.